Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Starling Oncology, Inc.TOI · Entity 5327 | Chief Operating Officer | March 17, 2023 | March 22, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Starling Oncology, Inc.
Report date March 17, 2023 · Filed March 22, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 242,992 |
Reported balance
After 2023-03-17 transaction · row 1
1 source rowRow 1 · 2023-03-17 · Grant · Acquired 67,667 · Balance 242,992 F1: Represents RSUs with 1/4th of the RSUs vesting on the anniversary of March 17, 2023 (the Vesting Commencement Date), with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.48 · Expires 2033-03-17 | Direct | 169,169 |
Reported balance
After 2023-03-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-17 · Grant · Acquired 169,169 · Balance 169,169 F2: The stock options vest as to 1/4th of the options granted on the first anniversary of the Vesting Commencement Date, with the remaining options vesting in four equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents RSUs with 1/4th of the RSUs vesting on the anniversary of March 17, 2023 (the Vesting Commencement Date), with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates.
F2: The stock options vest as to 1/4th of the options granted on the first anniversary of the Vesting Commencement Date, with the remaining options vesting in four equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2023 Filed Mar 22, 2023 00:56 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 169,169 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001628280-23-008832 · wf-form4_167944655124135.xml · derivative · entry 2 Miller Matthew P · CIK 0001915822 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,169 Underlying: Common stock · 169,169 shares Expires 2033-03-17 F2 · derivative.exercise_date: The stock options vest as to 1/4th of the options granted on the first anniversary of the Vesting Commencement Date, with the remaining options vesting in four equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. Read SEC document |
| March 17, 2023 Filed Mar 22, 2023 00:56 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon stock | 67,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-008832 · wf-form4_167944655124135.xml · nonDerivative · entry 1 Miller Matthew P · CIK 0001915822 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 242,992 F1 · shares: Represents RSUs with 1/4th of the RSUs vesting on the anniversary of March 17, 2023 (the Vesting Commencement Date), with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. Read SEC document |
| December 16, 2022 Filed Dec 21, 2022 01:07 UTC | Starling Oncology, Inc. TOI · Entity 5327 | PurchaseCommon Stock | 73,684 | $0.95 | $69,999.80 |
DisclosureSEC source: 0001799191-22-000058 · edgardoc.xml · nonDerivative · entry 1 Miller Matthew P · CIK 0001915822 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,325 F1 · shares: The purchase of common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 577 shares, with the reporting persons sale of shares of common stock on November 15, 2022. The reporting person has paid to the Issuer the full amount of the profit realized in connection with the short-swing transaction, less transaction costs, calculated in accordance with Section 16(b). Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 22:33 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 119,825 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001799191-22-000037 · edgardoc.xml · derivative · entry 2 Miller Matthew P · CIK 0001915822 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,825 Underlying: Common Stock · 119,825 shares Expires 2032-11-17 F2 · derivative.exercise_date: The stock options vest as to 1/4th of the options granted on the first anniversary of the Vesting Commencement Date, with the remaining options vesting in four equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 22:33 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 23,607 | $0.00 | $0.00 |
DisclosureSEC source: 0001799191-22-000037 · edgardoc.xml · nonDerivative · entry 1 Miller Matthew P · CIK 0001915822 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,641 F1 · price: Represents RSUs with 1/4th of the RSUs vesting on the anniversary of November 17, 2022 (the Vesting Commencement Date), with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 22:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | Disposition to issuerCommon Stock | 577 | $2.03 | $1,169.98 |
DisclosureSEC source: 0001799191-22-000013 · edgardoc.xml · nonDerivative · entry 1 Miller Matthew P · CIK 0001915822 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,034 F1 · kind: The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement. F2 · price: Price is the volume weighted average selling price of all sales by the Reporting Person on November 15, 2022 within a one-dollar range. Actual prices ranged from $2.022 to $2.028. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. Read SEC document |
| November 15, 2022 Filed Nov 23, 2022 01:07 UTC Amendment | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon Stock | 577 | $2.03 | $1,169.98 |
DisclosureSEC source: 0001799191-22-000051 · edgardoc.xml · nonDerivative · entry 1 Miller Matthew P · CIK 0001915822 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,034 F1 · kind: This Form 4/A amends and restates the reporting persons Form 4 originally filed on November 17, 2022 in the entirety. This Form 4/A is being filed to correct the reporting persons original Form 4 from Code D to Code S. The sales reported in the Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement. F2 · price: Price is the volume weighted average selling price of all sales by the Reporting Person on November 15, 2022 within a one-dollar range. Actual prices ranged from $2.022 to $2.028. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 23:34 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantStock Option (right to buy) · Derivative | 17,575 | $0.00 Strike: $7.09 | $0.00 |
DisclosureSEC source: 0001628280-22-007095 · wf-form4_164807848351583.xml · derivative · entry 4 Miller Matthew P · CIK 0001915822 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,575 Underlying: Common stock · 17,575 shares Expires 2032-03-21 F4 · derivative.exercise_date: The stock options vest as to 1/3rd of the options granted on the second anniversary of the Vesting Commencement Date, with the remaining options vesting in four equal annual installments beginning on the third anniversary of the Vesting Commencement Date, with all options becoming vested on the sixth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 23:34 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantStock Option (right to buy) · Derivative | 5,186 | $0.00 Strike: $7.09 | $0.00 |
DisclosureSEC source: 0001628280-22-007095 · wf-form4_164807848351583.xml · derivative · entry 3 Miller Matthew P · CIK 0001915822 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,186 Underlying: Common stock · 5,186 shares Expires 2032-03-21 F3 · derivative.exercise_date: The stock options vest in four equal annual installments on each of the first four anniversaries of the Vesting Commencement Date, with all options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 23:34 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon stock | 21,641 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-007095 · wf-form4_164807848351583.xml · nonDerivative · entry 2 Miller Matthew P · CIK 0001915822 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,611 F2 · shares: Represents RSUs with 1/3rd of the RSUs vesting on the second anniversary of the Vesting Commencement Date, with the remaining RSUs vesting in four equal annual installments beginning on the third anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the sixth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. F2 · price: Represents RSUs with 1/3rd of the RSUs vesting on the second anniversary of the Vesting Commencement Date, with the remaining RSUs vesting in four equal annual installments beginning on the third anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the sixth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 23:34 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon stock | 6,386 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-007095 · wf-form4_164807848351583.xml · nonDerivative · entry 1 Miller Matthew P · CIK 0001915822 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,970 F1 · shares: Represents restricted stock units ("RSUs") that vest in four equal annual installments on each of the first four anniversaries of November 12, 2021 (the "Vesting Commencement Date"), with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. F1 · price: Represents restricted stock units ("RSUs") that vest in four equal annual installments on each of the first four anniversaries of November 12, 2021 (the "Vesting Commencement Date"), with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. Read SEC document |
| March 21, 2022 Filed Mar 30, 2022 00:11 UTC Amendment | Starling Oncology, Inc. TOI · Entity 5327 | GrantStock Option (right to buy) · Derivative | 109,844 | $0.00 Strike: $7.09 | $0.00 |
DisclosureSEC source: 0001628280-22-007763 · wf-form4a_164859908108007.xml · derivative · entry 2 Miller Matthew P · CIK 0001915822 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,844 Underlying: Common stock · 109,844 shares Expires 2032-03-21 F2 · derivative.exercise_date: The stock options vest as to 1/3rd of the options granted on the second anniversary of the Vesting Commencement Date, with the remaining options vesting in four equal annual installments beginning on the third anniversary of the Vesting Commencement Date, with all options becoming vested on the sixth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. Read SEC document |
| March 21, 2022 Filed Mar 30, 2022 00:11 UTC Amendment | Starling Oncology, Inc. TOI · Entity 5327 | GrantStock Option (right to buy) · Derivative | 32,417 | $0.00 Strike: $7.09 | $0.00 |
DisclosureSEC source: 0001628280-22-007763 · wf-form4a_164859908108007.xml · derivative · entry 1 Miller Matthew P · CIK 0001915822 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,417 Underlying: Common stock · 32,417 shares Expires 2032-03-21 F1 · derivative.exercise_date: The stock options vest in four equal annual installments on each of the first four anniversaries of November 12, 2021 (the "Vesting Commencement Date"), with all options becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.